SGK1 INHIBITORS FOR TREATMENT OF PROSTATE CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 19, 2017
app pub date -
Dec 11, 2014
filing date -
Dec 11, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of SGK1 are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of SGK1 inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, SGK1 inhibitors also have Glucocorticoid Receptor (GR) and/or Androgen Receptor (AR) inhibitory activity or are administered in conjunction with GR and/or AR inhibitors.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully